| Ident. | Authors (with country if any) | Title |
|---|
| 000E83 (2017) |
A F Leary ; M. Quinn ; K. Fujiwara ; R L Coleman ; E. Kohn ; T. Sugiyama ; R. Glasspool ; I. Ray-Coquard ; N. Colombo ; M. Bacon ; A. Zeimet ; A. Westermann ; E. Gomez-Garcia ; D. Provencher ; S. Welch ; W. Small ; D. Millan ; A. Okamoto ; G. Stuart ; K. Ochiai | Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours. |
| 000F60 (2017) |
G A Mcarthur ; M. Maio ; A. Arance ; P. Nathan ; C. Blank ; M-F Avril ; C. Garbe ; A. Hauschild ; D. Schadendorf ; O. Hamid ; M. Fluck ; M. Thebeau ; J. Schachter ; R. Kefford ; M. Chamberlain ; M. Makrutzki ; S. Robson ; R. Gonzalez ; K. Margolin | Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. |
| 001112 (2017) |
M. Martín ; A. Chan ; L. Dirix ; J. O'Shaughnessy ; R. Hegg ; A. Manikhas ; M. Shtivelband ; P. Krivorotko ; N. Batista L Pez ; M. Campone ; M. Ruiz Borrego ; Q J Khan ; J T Beck ; M. Ramos Vázquez ; P. Urban ; S. Goteti ; E. Di Tomaso ; C. Massacesi ; S. Delaloge | A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). |
| 001127 (2017) |
F. Cardoso ; A. Costa ; E. Senkus ; M. Aapro ; F. André ; C H Barrios ; J. Bergh ; G. Bhattacharyya ; L. Biganzoli ; M J Cardoso ; L. Carey ; D. Corneliussen-James ; G. Curigliano ; V. Dieras ; N. El Saghir ; A. Eniu ; L. Fallowfield ; D. Fenech ; P. Francis ; K. Gelmon ; A. Gennari ; N. Harbeck ; C. Hudis ; B. Kaufman ; I. Krop ; M. Mayer ; H. Meijer ; S. Mertz ; S. Ohno ; O. Pagani ; E. Papadopoulos ; F. Peccatori ; F. Penault-Llorca ; M J Piccart ; J Y Pierga ; H. Rugo ; L. Shockney ; G. Sledge ; S. Swain ; C. Thomssen ; A. Tutt ; D. Vorobiof ; B. Xu ; L. Norton ; E. Winer | 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). |
| 001207 (2017) |
F. Cardoso ; A. Costa ; E. Senkus ; M. Aapro ; F. André ; C H Barrios ; J. Bergh ; G. Bhattacharyya ; L. Biganzoli ; M J Cardoso ; L. Carey ; D. Corneliussen-James ; G. Curigliano ; V. Dieras ; N. El Saghir ; A. Eniu ; L. Fallowfield ; D. Fenech ; P. Francis ; K. Gelmon ; A. Gennari ; N. Harbeck ; C. Hudis ; B. Kaufman ; I. Krop ; M. Mayer ; H. Meijer ; S. Mertz ; S. Ohno ; O. Pagani ; E. Papadopoulos ; F. Peccatori ; F. Pernault-Llorca ; M J Piccart ; J Y Pierga ; H. Rugo ; L. Shockney ; G. Sledge ; S. Swain ; C. Thomssen ; A. Tutt ; D. Vorobiof ; B. Xu ; L. Norton ; E. Winer | 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). |
| 001528 (2016) |
J C Soria ; H K Gan ; S P Blagden ; R. Plummer ; H T Arkenau ; M. Ranson ; T R J. Evans ; G. Zalcman ; R. Bahleda ; A. Hollebecque ; C. Lemech ; E. Dean ; J. Brown ; D. Gibson ; V. Peddareddigari ; S. Murray ; N. Nebot ; J. Mazumdar ; L. Swartz ; K R Auger ; R A Fleming ; R. Singh ; M. Millward | A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. |
| 001730 (2016) |
D. Fumagalli ; T R Wilson ; R. Salgado ; X. Lu ; J. Yu ; C. O'Brien ; K. Walter ; L Y Huw ; C. Criscitiello ; I. Laios ; V. Jose ; D N Brown ; F. Rothé ; M. Maetens ; D. Zardavas ; P. Savas ; D. Larsimont ; M J Piccart-Gebhart ; S. Michiels ; M R Lackner ; C. Sotiriou ; S. Loi | Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. |
| 001750 (2016) |
G V Long ; V. Atkinson ; P A Ascierto ; C. Robert ; J C Hassel ; P. Rutkowski ; K J Savage ; F. Taylor ; C. Coon ; I. Gilloteau ; H B Dastani ; I M Waxman ; A P Abernethy | Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. |
| 001859 (2016) |
B. Escudier ; C. Porta ; M. Schmidinger ; N. Rioux-Leclercq ; A. Bex ; V. Khoo ; V. Gruenvald ; A. Horwich | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| 001881 (2016) |
B. Solomon ; J-C Soria | The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overview. |
| 001905 (2016) |
O. Le Saux ; C. Falandry ; H K Gan ; B. You ; G. Freyer ; J. Péron | Inclusion of elderly patients in oncology clinical trials. |
| 001982 (2016) |
F. Trillsch ; S. Mahner ; F. Hilpert ; L. Davies ; E. García-Martínez ; G. Kristensen ; A. Savarese ; P. Vuylsteke ; M. Los ; F. Zagouri ; L. Gladieff ; J. Sehouli ; C. Khoon Lee ; V. Gebski ; E. Pujade-Lauraine | Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. |
| 001A34 (2016) |
K. Lindemann ; G. Kristensen ; M R Mirza ; L. Davies ; F. Hilpert ; I. Romero ; A. Ayhan ; A. Burges ; M J Rubio ; F. Raspagliesi ; M. Huizing ; G-J Creemers ; M. Lykka ; C K Lee ; V. Gebski ; E. Pujade-Lauraine | Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. |
| 001A38 (2016) |
E. Van Cutsem ; A. Cervantes ; R. Adam ; A. Sobrero ; J H Van Krieken ; D. Aderka ; E. Aranda Aguilar ; A. Bardelli ; A. Benson ; G. Bodoky ; F. Ciardiello ; A. D'Hoore ; E. Diaz-Rubio ; J-Y Douillard ; M. Ducreux ; A. Falcone ; A. Grothey ; T. Gruenberger ; K. Haustermans ; V. Heinemann ; P. Hoff ; C-H Köhne ; R. Labianca ; P. Laurent-Puig ; B. Ma ; T. Maughan ; K. Muro ; N. Normanno ; P. Österlund ; W J G. Oyen ; D. Papamichael ; G. Pentheroudakis ; P. Pfeiffer ; T J Price ; C. Punt ; J. Ricke ; A. Roth ; R. Salazar ; W. Scheithauer ; H J Schmoll ; J. Tabernero ; J. Taïeb ; S. Tejpar ; H. Wasan ; T. Yoshino ; A. Zaanan ; D. Arnold | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. |
| 001B44 (2016) |
C. Swanton ; J-C Soria ; A. Bardelli ; A. Biankin ; C. Caldas ; S. Chandarlapaty ; L. De Koning ; C. Dive ; J. Feunteun ; S-Y Leung ; R. Marais ; E R Mardis ; N. Mcgranahan ; G. Middleton ; S A Quezada ; J. Rod N ; N. Rosenfeld ; C. Sotiriou ; F. André | Consensus on precision medicine for metastatic cancers: a report from the MAP conference. |
| 001B97 (2016) |
M. Chatterjee ; D C Turner ; E. Felip ; H. Lena ; F. Cappuzzo ; L. Horn ; E B Garon ; R. Hui ; H-T Arkenau ; M A Gubens ; M D Hellmann ; D. Dong ; C. Li ; K. Mayawala ; T. Freshwater ; M. Ahamadi ; J. Stone ; G M Lubiniecki ; J. Zhang ; E. Im ; D P De Alwis ; A G Kondic ; Fl Tten | Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. |
| 001D44 (2016) |
J R Mackey ; T. Pie Kowski ; J. Crown ; S. Sadeghi ; M. Martin ; A. Chan ; M. Saleh ; S. Sehdev ; L. Provencher ; V. Semiglazov ; M F Press ; G. Sauter ; M. Lindsay ; V. Houé ; M. Buyse ; P. Drevot ; S. Hitier ; S. Bensfia ; W. Eiermann | Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. |
| 001E10 (2016) |
N. Harbeck ; S. Iyer ; N. Turner ; M. Cristofanilli ; J. Ro ; F. André ; S. Loi ; S. Verma ; H. Iwata ; H. Bhattacharyya ; K. Puyana Theall ; C H Bartlett ; S. Loibl | Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. |
| 002070 (2016) |
R K Ramanathan ; D. Goldstein ; R L Korn ; F. Arena ; M. Moore ; S. Siena ; L. Teixeira ; J. Tabernero ; J-L Van Laethem ; H. Liu ; D. Mcgovern ; B. Lu ; D D Von Hoff | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. |
| 002539 (2016) |
J. Bridgewater ; A. Lopes ; H. Wasan ; D. Malka ; L. Jensen ; T. Okusaka ; J. Knox ; D. Wagner ; D. Cunningham ; J. Shannon ; D. Goldstein ; M. Moehler ; T. Bekaii-Saab ; M G Mcnamara ; J W Valle | Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. |
| 002540 (2016) |
D. Maillet ; J Y Blay ; B. You ; A. Rachdi ; H K Gan ; J. Péron | The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. |
